Cernostics CEO Michael Hoerres said his biotech company’s presence will not just remain but grow in Pittsburgh with the pending acquisition by Castle Biosciences Inc.

On Wednesday, Castle Biosciences Inc. announced it would acquire Cernostics for $30 million with the potential for $50 million more in cash and stock with the achievement of certain milestones.

– See more at: